International enterprises from pharmaceutical sector and unfair competition
Article Sidebar
Main Article Content
Abstract
Multinational enterprises increasingly exploit their institutional advantages by consciously influencing institutions in the expansion market in such a way as to protect corporate interests. To a large extent, this can apply to multinational pharmaceutical companies operating in highly regulated markets, both on the demand and the supply side. The aim of the study was to analyze the actions taken by global pharmaceutical corporations present on the Polish market to influence the institutions of national regulators in order to prevent unfair and unethical competition. The study was of a qualitative nature and covered three very large pharmaceutical entities in Poland. The surveyed companies actively tried to co-create the institutional environment of the target country, in this case the Polish market. At the same time, to a much lesser extent, they took actions to limit unfair competition by means of their institutional advantages, relying primarily on the use of traditional competitive advantages concept.
Downloads
Article Details
The author of the article declares that the submitted article does not infringe the copyrights of third parties. The author agrees to subject the article to the review procedure and to make editorial changes. The author transfers, free of charge, to SGH Publishing House the author's economic rights to the work in the fields of exploitation listed in the Article 50 of the Act of 4 February 1994 on Copyright and Related Rights – provided that the work has been accepted for publication and published.
SGH Publishing House holds economic copyrights to all content of the journal. Placing the text of the article in a repository, on the author's home page or on any other page is allowed as long as it does not involve obtaining economic benefits, and the text will be provided with source information (including the title, year, number and internet address of the journal).
References
Brycz B., Dudycz T. (2010), Case study jako popularna metoda w naukach o zarządzaniu, „Kwartalnik Nauk o Przedsiębiorstwie”, nr 3.
Ginsburg G.S., McCarthy J.J. (2011), Personalized medicine: revolutionizing drug discovery and patient care, „Trends in Biotechnology”, No 11.
Masi J.A. (2016), Innovation in the pharmaceutical industry: New estimates of R&D costs, „Journal of Health Economics”, Vol. 47, No. 1, p. 20-33.
Sagan M. (2016), Instytucjonalne zaangażowanie korporacji międzynarodowych a trwała przewaga konkurencyjna, „Ekonomika i Organizacja Przedsiębiorstwa”, nr 11, s. 31-32.
Sagan M. (2018), Przewagi instytucjonalne przedsiębiorstw międzynarodowych, „Ekonomika i Organizacja Przedsiębiorstwa”, nr 3, s. 46-48.
Saha C.N., Bhattacharya S. (2011), Intellectual property rights: An overview and implications in pharmaceutical industry, „Journal of Advanced Pharmaceutical and Technological Research”, nr 6.
Lehman B. (2018), The Pharmaceutical Industry and the Patent System, https://users.wfu.edu/mcfallta/DIR0/pharma_patents.pdf (dostęp 21.11.2020).
Second Patent Cliff Lies Ahead for Pharma With $251 Billion in Sales at Risk by 2024, https://www.centerforbiosimilars.com/news/second-patent-cliff-lies-ahead-for-pharma-with-251-billion-in-sales-at-risk-by-2024 (dostęp 5.11.2018).